Domestic innovative drugs and research results are presented at the top international conferences ASCO and WCLC, demonstrating China's pharmaceutical innovation strength
Recently, China's innovative drug field has ushered in a highlight moment, and the breakthrough achievements of many pharmaceutical companies and research institutions have appeared at the top international academic conferences - the American Society of Clinical Oncology (ASCO) Annual Meeting and the World Lung Cancer Conference (WCLC). These advances not only showcase China's rapid progress in the field of oncology treatment, but also provide more treatment options for patients around the world. The following are the hot topics and structured data analysis of domestic innovative drugs that have been hotly discussed across the Internet in the past 10 days.
1. China's strength at the ASCO and WCLC meetings
At the 2024 ASCO and WCLC meeting, the number of clinical studies submitted by the Chinese team hit a record high, covering multiple cancers such as lung cancer, breast cancer, and gastric cancer. Among them, PD-1/PD-L1 inhibitors, ADCs (antibody-conjugated drugs), CAR-T cell therapy, etc. have become the focus.
| Pharmaceutical companies/institutions | field of study | Core results | International attention |
|---|---|---|---|
| Hengrui Medicine | PD-1 inhibitor (Carelilizumab) | Positive results for the first-line treatment of gastric cancer | High (selected in the ASCO oral report) |
| BeiGene | PARP inhibitor (Pamiparib) | Updated data on maintenance treatment of ovarian cancer | Medium-high |
| Innobi | ADC drug (IBI315) | HER2-positive breast cancer phase II data released for the first time | high |
| Keji Pharmaceutical | CAR-T Therapy (CT053) | Long-term follow-up data for multiple myeloma | middle |
2. Analysis of key research results
1.Hengrui Medicine: Breakthrough in the treatment of gastric cancer
A phase III study of carilizumab combined with chemotherapy (NCT03802591) showed that the patient's median progression-free survival (PFS) was significantly extended (7.7 months vs 5.3 months), becoming the first domestic first-line treatment plan for gastric cancer to announce positive results at ASCO.
2.Innovent Biologics: New progress in ADC drugs
Phase II data of IBI315 (HER2/CD3 dual antibody) shows that the objective response rate (ORR) of HER2-positive breast cancer reached 45.8%, and its safety is better than similar imported drugs, causing heated discussions in the industry about "domestic ADC replacement".
| Drug Type | Representative domestic medicine | Key data comparison (ORR/PFS) | International competitive product benchmarking |
|---|---|---|---|
| PD-1 inhibitor | Carrelizumab | ORR 64.1% (gastric cancer) | Keytruda |
| ADC drugs | IBI315 | ORR 45.8% (Breast Cancer) | Enhertu |
| CAR-T Therapy | CT053 | 12-month PFS rate 78% | Abecma |
3. Industry impact and future trends
1.The internationalization process is accelerating
Since 2024, the overseas authorized transaction volume of domestic innovative drugs has exceeded US$5 billion, an increase of 120% year-on-year. The performance of ASCO/WCLC will further promote the License-out cooperation.
2.Policy support effect appears
The National Medical Products Administration's "Breakthrough Therapeutic Drugs" channel has granted 12 domestic tumor drugs qualifications, of which 6 of which released the latest data in this meeting.
3.Challenges and opportunities coexist
Although the clinical data are impressive, domestic drugs still need breakthroughs in overseas commercialization capabilities and the depth of biomarker research. Experts predict that China's global market share in innovative drugs is expected to increase from the current 3% to 8% in 2025.
Conclusion
From "following" to "running side by side", China's innovative drugs occupy an increasingly important position in the international stage. With the discovery of more original targets and the verification of clinical value, domestic pharmaceutical companies are expected to achieve a leap from "quantitative change" to "qualitative change" in the next five years.
check the details
check the details
en
